Strikingly, in mixed-lineage leukemia, activation of Wnt signaling was sufficient to (partially) revert anti-tumor effects of GSK-3β inhibition, and combined blockage of GSK-3β and β-catenin was required to achieve tumor regression [43]. This evidence concerns the gene GSK3B and leukemia.